je.st
news
Tag: study
MSD Announces Positive Study Investigating the Use of Pembrolizumab Compared to Chemotherapy in Patients with Ipilimumab-Refractory Advanced Melanoma
2014-11-16 10:25:00| Merck.com - Research & Development News
Dateline City: ZURICH Pembrolizumab Demonstrated Superiority to Chemotherapy for Primary Endpoint of Progression-Free Survival Findings Presented for First Time at Society of Melanoma Research (SMR) 2014 International Congress ZURICH--(BUSINESS WIRE)--MSD, known as Merck in the United States and Canada, announced today that a pre-specified analysis of investigational data from a pivotal Phase 2 study (KEYNOTE-002) showed pembrolizumab, the companys anti-PD-1 therapy, substantially improved the primary endpoint of progression-free survival (PFS, as assessed by RECIST 1.1, independent central review) (HR 0.57 and 0.50 for 2 mg/kg and 10 mg/kg every three week doses, respectively), compared to chemotherapy (P<0.0001 for both comparisons) in patients with ipilimumab- Language: English Contact: MSDMedia:Lainie Keller, +1-908-236-5036Claire Mulhearn, +1-908-236-1118orInvestor:Joseph Romanelli, +1-908-423-5185Justin Holko, +1-908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: with
advanced
study
positive
Merck Announces Positive Study Investigating the Use of KEYTRUDA (pembrolizumab) Compared to Chemotherapy in Patients with Ipilimumab-Refractory Advanced Melanoma
2014-11-16 10:25:00| Merck.com - Research & Development News
Dateline City: ZURICH KEYTRUDA Demonstrated Superiority to Chemotherapy for Primary Endpoint of Progression-Free Survival Findings Presented for First Time at Society of Melanoma Research (SMR) 2014 International Congress ZURICH--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that a pre-specified analysis of investigational data from a pivotal Phase 2 study (KEYNOTE-002) showed KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, substantially improved the primary endpoint of progression-free survival (PFS, as assessed by RECIST 1.1, independent central review) (HR 0.57 and 0.50 for 2 mg/kg and 10 mg/kg every three week doses, respectively), compared to chemotherapy (P<0.0001 for both comparisons) Language: English Contact: MerckMedia:Lainie Keller, 908-236-5036Claire Mulhearn, 908-236-1118orInvestor:Joseph Romanelli, 908-423-5185Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: with
advanced
study
positive
Study ordered to expand toll lanes on freeways
2014-11-15 12:42:11| Railroads - Topix.net
The San Gabriel Valley Tribune says Los Angeles County's transit agency directed staff on Thursday to develop a plan for turning more free carpool lanes into pay-to-ride lanes. John Fasana, a member of the Metropolitan Transportation Authority, says Interstates 5, 405 and 210 will be studied, along with possibly extending the current and popular toll lanes on Interstates 10 and 110.
Tags: study
expand
toll
ordered
Philadelphia biotech firm gets $3.5M NIH contract to study Ebola, hepatits C viruses
2014-11-15 12:08:06| Biotech - Topix.net
The National Institutes of Health awarded Integral Molecular Inc. a five-year, $3.5 million contract to study the human immune response to the Ebola virus and hepatitis C virus. The funding will enable the Philadelphia biotechnology company to better understand how human antibodies protect, or fail to protect, people against such viruses.
Tags: study
firm
contract
philadelphia
Climate Change To Make Lightning More Common, Study Says
2014-11-14 17:13:00| Climate Ark Climate Change & Global Warming Newsfeed
National Public Radio: The likelihood of getting struck by lightning has long been a metaphor for something with an exceedingly remote probability. But that could be changing. A new study in the journal Science says that temperature increases due to climate change are ushering in a new era that could mean by the end of the century lightning strikes will be about half again as common as they were at the start of this century. That's because lightning occurs more frequently when it's hotter. To wit, Florida leads...
Tags: make
change
study
common
Sites : [578] [579] [580] [581] [582] [583] [584] [585] [586] [587] [588] [589] [590] [591] [592] [593] [594] [595] [596] [597] next »